BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025)
BridgeBio Pharma (BBIO) posted Tax Provisions of -$165000.0 for Q4 2025, up 89.32% sequentially from -$1.5 million in Q3 2025, and down 114.31% YoY from $1.2 million in Q4 2024.
BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025) Analysis & Trends
BridgeBio Pharma has reported Tax Provisions for 2 years, with the latest figure at -$165000.0 in Q4 2025.
- Quarterly Tax Provisions fell 114.31% year-over-year to -$165000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $435000.0, down 62.27% from the prior year.
- Tax Provisions rose to -$165000.0 in Q4 2025 per BBIO's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Tax Provisions peaked at $2.1 million in Q2 2025 and troughed at -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -165,000.00 |
| Sep 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Dec 31, 2024 | 1.15 Mn |